DBV Technologies S.A.

AI-generated fair value estimate for this company.

Method: Net cash floor method: $174.90M cash and equivalents minus $7.70M total debt = $167.2M net cash, divided by 295.92M shares outstanding = $0.57/share.

Reasoning: DBV Technologies is a clinical-stage biopharmaceutical company with only $5.04M of revenue against a $175.95M annual net loss, so its pipeline's value depends on binary, unpredictable trial/regulatory outcomes that cannot be rigorously modeled; net cash is the only fundamentally grounded floor value, deliberately excluding speculative pipeline optionality.